Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 in HCC awaiting liver transplant
NCT06337162Phase 1Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- May 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of incb099280 in hepatocellular carcinoma (HCC), sponsored by Abramson Cancer Center. Primary endpoint: Acute Cellular Rejection of Liver Transplant Attributed to Study Therapy. Planned start May 2024; status: withdrawn.
02
Drugs
incb099280
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06337162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337162.